Enanta Pharma (ENTA) Tops Q4 EPS by 14c

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of $0.29, $0.14 better than the analyst estimate of $0.15. Revenue for the quarter came in at $14.4 million versus the consensus estimate of $16.44 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Prosperity Bancshares (PB) Reiterated at Overweight by Cantor Fitzgerald as Estimates Revised
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'